SCHEMBL26984973

SCHEMBL26984973

Cc1c(Cc2ccnc(O)n2)cncc1Nc1ccc(Cl)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NUDT1 P36639 4/20 0.44
▸ FLT1 P17948 6/20 0.37
▸ KDR P35968 6/20 0.37
▸ FGFR1 P11362 3/20 0.37
▸ TRPM5 Q9NZQ8 1/20 0.35
▸ EGFR P00533 3/20 0.35
▸ GPR52 Q9Y2T5 1/20 0.34
▸ ERBB2 P04626 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ PDGFRB P09619 1/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ EPHB2 P29323 1/20 0.33
▸ FLT4 P35916 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30746461 1.00 NUDT1 (0.44) NUDT1FLT1KDRFGFR1TRPM5
SCHEMBL30746493 0.89 NUDT1 (0.43) NUDT1FLT1KDRFGFR1TRPM5
SCHEMBL26985099 0.89 NUDT1 (0.43) NUDT1FLT1KDRFGFR1TRPM5
SCHEMBL26985260 0.88 NUDT1 (0.42) NUDT1FLT1KDRFGFR1TRPM5
SCHEMBL30746523 0.88 NUDT1 (0.42) NUDT1FLT1KDRFGFR1TRPM5
SCHEMBL26985111 0.82 NUDT1 (0.40) NUDT1FLT1KDRFGFR1GPR52
SCHEMBL30746584 0.82 NUDT1 (0.40) NUDT1FLT1KDRFGFR1GPR52
SCHEMBL30746528 0.80 NUDT1 (0.47) NUDT1FLT1KDRFGFR1TRPM5
SCHEMBL26985139 0.80 NUDT1 (0.47) NUDT1FLT1KDRFGFR1TRPM5
SCHEMBL26984868 0.79 NUDT1 (0.42) NUDT1FLT1KDRFGFR1TRPM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 — — US disclosed
WO-2024010925-A2 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001845-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK6, MAPK3, MAPK1 NUDT1 1810/4885FLT1 3167/4885KDR 818/4885
US-20250288571-A1 MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS BRAF, MAP3K1, MAP3K5 NUDT1 2559/4885FLT1 1164/4885KDR 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback